Edvince receives approval from the Ethics Committee on Clinical Application for EDV2209 in subarachnoid haemorrhage (SAH)

Edvince received approval from Ethics Committee for the study “Interventional, randomised, double-blind, placebo-controlled, multiple-ascending-dose, first-in-human trial to determine the safety and tolerability of the MEK1/2 inhibitor EDV2209 in patients with Subarachnoid Haemorrhage – SAH”, protocol no./code EDV2209_01, EudraCT no. 2021-003629-31